Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 17, 2025 07:30 ET | Source: CervoMed Inc.

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company),...
September 03, 2025 08:00 ET | Source: CervoMed Inc.

CervoMed to Participate in Upcoming Investor Conferences

BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company...
August 11, 2025 08:00 ET | Source: CervoMed Inc.

CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Reported 32-week data from Phase 2b RewinD-LB Trial Extension phase showing neflamapimod treatment resulted in a substantial reduction in clinically significant worsening compared to control arm over...
August 05, 2025 08:00 ET | Source: CervoMed Inc.

CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference

BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company...
July 28, 2025 07:00 ET | Source: CervoMed Inc.

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at...
July 24, 2025 16:05 ET | Source: CervoMed Inc.

CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025

Company to share primary endpoint results at 32-Weeks from Extension phase following late-breaking presentations at Alzheimer's Association International Conference® (AAIC) 2025 Conference call and...
July 08, 2025 07:00 ET | Source: CervoMed Inc.

CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025

BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will...
June 10, 2025 08:00 ET | Source: CervoMed Inc.

CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization

Strengthening CMC leadership to prepare for scaled up neflamapimod manufacturing On track to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory authorities ...
May 12, 2025 08:00 ET | Source: CervoMed Inc.

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB)...
May 07, 2025 08:00 ET | Source: CervoMed Inc.

CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference

BOSTON, May 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today...